ABL1 and metabolic syndrome: The 1st generation BCR-ABL TKI imatinib causes in 0.1–1% of cases hypertension, heart failure, hyperglycemia, and pleural effusion, while 2nd generation nolitinib causes hypertension, QTc prolongation, atrial fibrillation, dyslipidemia, and vascular toxicity (1–10%).